Top Page
Oscar Health
(NYSE:OSCR)
Oscar Health (OSCR) vs. SPDR S&P 500 ETF (SPY)
Oscar Health Business Overview & Revenue Model
Oscar Health Earnings Call Summary
Oscar Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.73B | 9.18B | 5.86B | 4.13B | 1.92B | 589.64M |
| Gross Profit | 10.73B | 9.18B | 5.86B | 4.13B | 1.92B | 589.64M |
| EBITDA | -97.21M | 89.31M | -212.00M | -572.17M | -551.25M | -390.98M |
| Net Income | -161.23M | 25.43M | -270.73M | -606.27M | -572.61M | -406.82M |
Balance Sheet | ||||||
| Total Assets | 6.38B | 4.84B | 3.60B | 4.53B | 3.32B | 2.27B |
| Cash, Cash Equivalents and Short-Term Investments | 3.54B | 2.15B | 2.56B | 2.96B | 1.69B | 1.19B |
| Total Debt | 299.94M | 299.56M | 298.78M | 298.00M | 0.00 | 142.49M |
| Total Liabilities | 5.22B | 3.82B | 2.80B | 3.63B | 440.02M | 3.57B |
| Stockholders Equity | 1.16B | 1.01B | 803.97M | 890.38M | 1.39B | -1.30B |
Cash Flow | ||||||
| Free Cash Flow | 1.20B | 950.30M | -297.74M | 351.34M | -207.63M | 208.71M |
| Operating Cash Flow | 1.23B | 978.19M | -272.16M | 380.35M | -181.75M | 222.73M |
| Investing Cash Flow | -951.65M | -1.39B | 577.19M | -226.52M | -774.51M | -344.71M |
| Financing Cash Flow | 49.38M | 68.39M | 6.45M | 301.11M | 1.24B | 611.71M |
Oscar Health Technical Analysis
Oscar Health Risk Analysis
Oscar Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $33.46B | 21.35 | 9.03% | 1.21% | 9.88% | -7.25% | |
| ― | $17.38B | ― | -21.93% | ― | 14.92% | -286.72% | |
| ― | $7.87B | 9.49 | 19.71% | ― | 13.71% | -18.02% | |
| ― | $3.37B | ― | -15.06% | ― | 47.39% | 85.35% | |
| ― | $4.65B | ― | -14.04% | ― | 48.29% | -1436.25% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.81B | ― | -12.59% | ― | -4.87% | 66.16% |
Oscar Health Corporate Events
On September 18, 2025, Oscar Health, Inc. issued $410 million in Convertible Senior Subordinated Notes due 2030, with net proceeds of approximately $395.8 million. The funds will support strategic initiatives, including AI-driven expansion and enhanced consumer healthcare experiences, while also addressing potential growth opportunities like premium tax credits.
The most recent analyst rating on (OSCR) stock is a Sell with a $11.00 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.
On September 16, 2025, Oscar Health announced the pricing of its upsized $355 million offering of 2.25% convertible senior subordinated notes due 2030, aimed at scaling long-term growth and adoption in the individual market. The proceeds from this offering will support general corporate purposes, including strategic AI initiatives and potential extension of premium tax credits, while also managing share dilution through capped call transactions.
The most recent analyst rating on (OSCR) stock is a Sell with a $11.00 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.
On September 11, 2025, Oscar Health, Inc. amended its investment agreement to facilitate a private offering of $350 million in convertible senior subordinated notes due 2030. The proceeds from this offering are intended to support Oscar’s long-term growth initiatives, including strategic AI projects and enhancing consumer healthcare experiences, as well as potentially terminating its revolving credit facility.
The most recent analyst rating on (OSCR) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.
Oscar Health, Inc. announced its participation in the 2025 Wells Fargo Healthcare Conference on September 3, 2025. During the event, the company plans to reaffirm its updated full-year 2025 guidance, which was initially shared in its preliminary financial results for the second quarter of 2025. This move is likely to impact the company’s operations by reinforcing its financial outlook and could influence stakeholder confidence.
The most recent analyst rating on (OSCR) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.
Oscar Health’s recent earnings call conveyed a mixed sentiment, reflecting both optimism and challenges. The company reported significant revenue growth and strategic initiatives aimed at long-term stability, such as acquisitions and expense management. However, Oscar Health faces hurdles with increased medical loss ratios, operating losses, and market morbidity, impacting its short-term financial performance. Despite these challenges, the company remains hopeful about future profitability and market stabilization.
Oscar Health, Inc. is a healthcare technology company that focuses on providing Individual & Family plans and health technology solutions, aiming to make healthcare more accessible and affordable. In its latest earnings report for the second quarter of 2025, Oscar Health announced a significant increase in total revenue, reaching approximately $2.9 billion, up from $2.2 billion in the same period last year. However, the company also reported a net loss of $228.4 million, a stark contrast to the net income of $56.2 million in the second quarter of 2024. This loss was primarily attributed to an increased medical loss ratio of 91.1%, up from 79.0% the previous year, driven by higher market morbidity.